JP2024528705A - がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 - Google Patents

がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 Download PDF

Info

Publication number
JP2024528705A
JP2024528705A JP2024503903A JP2024503903A JP2024528705A JP 2024528705 A JP2024528705 A JP 2024528705A JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024528705 A JP2024528705 A JP 2024528705A
Authority
JP
Japan
Prior art keywords
cancer
creatine
rgx
kras
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528705A5 (enExample
Inventor
マスード タヴァゾイ
イザベル カース
デイビッド ダースト
Original Assignee
インスピルナ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスピルナ，インコーポレイテッド filed Critical インスピルナ，インコーポレイテッド
Publication of JP2024528705A publication Critical patent/JP2024528705A/ja
Publication of JP2024528705A5 publication Critical patent/JP2024528705A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024503903A 2021-07-20 2022-07-19 がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 Pending JP2024528705A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223926P 2021-07-20 2021-07-20
US63/223,926 2021-07-20
PCT/US2022/073884 WO2023004308A1 (en) 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer

Publications (2)

Publication Number Publication Date
JP2024528705A true JP2024528705A (ja) 2024-07-30
JP2024528705A5 JP2024528705A5 (enExample) 2025-07-25

Family

ID=84979767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503903A Pending JP2024528705A (ja) 2021-07-20 2022-07-19 がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法

Country Status (6)

Country Link
US (1) US20240180912A1 (enExample)
EP (1) EP4373582A4 (enExample)
JP (1) JP2024528705A (enExample)
AU (1) AU2022316200A1 (enExample)
CA (1) CA3225305A1 (enExample)
WO (1) WO2023004308A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
CN116602948B (zh) * 2023-06-06 2024-12-06 湖南岳靶生物医药有限公司 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用
WO2025114580A1 (en) * 2023-11-30 2025-06-05 National And Kapodistrian University Of Athens N-aminoguanidine derivatives with anticancer activity
CN121873253A (zh) * 2026-01-20 2026-04-17 合肥综合性国家科学中心大健康研究院 抗slc6a8的抗体或其抗原结合片段及其组合物和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190125706A1 (en) * 2012-10-31 2019-05-02 The Rockefeller University Treatment and diagnosis of colon cancer
US20190367926A1 (en) * 2014-12-26 2019-12-05 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2021062157A1 (en) * 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021079302A1 (en) * 2019-10-22 2021-04-29 Lupin Limited Pharmaceutical combination of prmt5 inhibitors
WO2021119316A1 (en) * 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176636A1 (en) * 2015-04-30 2016-11-03 Rgenix, Inc. Inhibitors of creatine transport and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190125706A1 (en) * 2012-10-31 2019-05-02 The Rockefeller University Treatment and diagnosis of colon cancer
US20190367926A1 (en) * 2014-12-26 2019-12-05 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2021062157A1 (en) * 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021079302A1 (en) * 2019-10-22 2021-04-29 Lupin Limited Pharmaceutical combination of prmt5 inhibitors
WO2021119316A1 (en) * 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEACH, vol. 78(13_Supplement), JPN6026030689, 2018, pages 5863, ISSN: 0005913074 *
EUROPEAN JOURNAL OF CANCER, vol. 138(Sup2), JPN6026030692, 2020, pages 2, ISSN: 0005913076 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.38, No.15_suppl, JPN6026030690, 2020, pages 3504, ISSN: 0005913075 *

Also Published As

Publication number Publication date
EP4373582A1 (en) 2024-05-29
WO2023004308A1 (en) 2023-01-26
US20240180912A1 (en) 2024-06-06
AU2022316200A1 (en) 2024-01-25
CA3225305A1 (en) 2023-01-26
EP4373582A4 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
Shapiro et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
US20210290620A1 (en) Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
JP2024526145A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤を含む組合せ医薬及び癌の治療のためのその使用
BR112021015632A2 (pt) Combinação farmacêutica que compreende tno155 e ribociclibe
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
EP4373582A1 (en) Compositions and methods for inhibiting creatine transport as a treatment for cancer
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
JP7422084B2 (ja) Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
AU2019388900A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
EP4650006A2 (en) Use of a kras g12c inhibitor in treating cancers
Konar et al. Synthesis and clinical development of palbociclib: An overview
US10220091B2 (en) Combination treatments with sonic hedgehog inhibitors
CA3140146A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP2991650A1 (en) Methods for the treatment of cancer
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
US20130150386A1 (en) Methods for the treatment of lung cancer
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
EP4157280A1 (en) Belvarafenib for use in cancer treatment
US20260116962A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250716

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260728